FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight ...
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Lilly's tirzepatide shows additional 21.1% weight loss after 12 …
Oct 15, 2023 · In a co-primary endpoint, following the lead-in period, participants taking tirzepatide achieved an additional 21.1% mean weight loss. In a secondary endpoint, participants achieved a total mean weight loss of 26.6% (29.2 kg or 64.4 lb.) from study entry over 84 weeks.
FDA approves Zepbound® (tirzepatide) as the first and only …
Dec 20, 2024 · "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity. Nearly half of clinical trial patients saw such improvements that they no longer had symptoms associated with OSA, marking a critical step forward in reducing the burden of this disease and its ...
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with ...
INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding ...
Aug 27, 2024 · In a clinical study, tirzepatide 5 mg, along with a reduced calorie diet and increased physical activity, achieved an average of 15% weight loss over 72 weeks compared to 3.1% for placebo. Zepbound is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like ...
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first …
May 13, 2022 · While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint. Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to be available in the U.S. in the coming weeks
Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in ...
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the ...
INDIANAPOLIS, Oct. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. The FDA grants Fast Track designation to ...
News Release - Eli Lilly and Company
Apr 17, 2024 · Based on these results, Lilly plans to submit to the U.S. Food and Drug Administration (FDA) and other global regulatory agencies beginning mid-year. Lilly received FDA Fast Track designation for moderate-to-severe OSA and obesity.
News Release - Eli Lilly and Company
Aug 20, 2024 · These topline results provide evidence for reduced risk of progression to type 2 diabetes and long-term maintenance of weight loss with tirzepatide in adults with pre-diabetes and obesity or overweight.
- Some results have been removed